Latvian biotech startup Cellbox Labs raises €3.3M

Latvian biotech startup Cellbox Labs has raised €3.3M to further develop its product portfolio. Part of this funding comes from government support as part of the Tech4Cure project.

Founded in 2020 in Riga by Arturs Abols, Gatis Mozolevskis, and Roberts Rimša, Cellbox Labs develops an organ-on-chip technology, which is based on the creation of miniature replicas of human organs (gut, lung) outside of the human organism, thus reducing animal testing in research. These replicas can be used to test various biological processes and for drug development. This technology allows for more accurate predictions of a drug's efficacy and toxicity during the development phase.

Additionally, Cellbox Labs is developing an automated organ-on-chip cultivation device that ensures high productivity, reduces the impact of human error, and minimizes the need for manual intervention.

In 2024 startup has raised €935K in a pre-seed round, led by Latvian Buildit VC, with participation from a syndicate of 12 LatBAN’s angels, managed by Girts Licis, Latvian investment fund ASP Asset Management AIFP, and its owner Ansis Spridzans.